Stockscreener 앱 받기
1.06
1.85%
-0.02
시간 외 거래:
1.06
전일 마감가:
$1.08
열려 있는:
$1.09
하루 거래량:
269.89K
Relative Volume:
0.25
시가총액:
$106.38M
수익:
-
순이익/손실:
$-20.31M
주가수익비율:
-4.0076
EPS:
-0.2645
순현금흐름:
$-21.07M
1주 성능:
+1.92%
1개월 성능:
+11.58%
6개월 성능:
+43.65%
1년 성능:
+7.29%
1일 변동 폭
$1.05
$1.10
1주일 범위
$1.02
$1.245
52주 변동 폭
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
ONCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.06 | 109.35M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 개시 | Lake Street | Buy |
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Is Oncolytics Biotech Inc. a speculative investmentNew Guidance & High Accuracy Swing Entry Alerts - خودرو بانک
What’s next for Oncolytics Biotech Inc. stockEarnings Recap Report & Stepwise Swing Trade Plans - خودرو بانک
What is Oncolytics Biotech Inc.’s TAM (Total Addressable Market)Weekly Investment Summary & Weekly High Return Forecasts - خودرو بانک
Multi asset correlation models including Oncolytics Biotech Inc.2025 Top Gainers & High Accuracy Buy Signal Tips - Newser
Will Oncolytics Biotech Inc. stock recover after recent dropBond Market & Fast Entry and Exit Trade Plans - Newser
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Quantisnow
Technical signs of recovery in Oncolytics Biotech Inc.2025 Macro Impact & Reliable Volume Spike Trade Alerts - Newser
Chart overlay techniques for tracking Oncolytics Biotech Inc.Trade Analysis Report & Low Drawdown Investment Strategies - Newser
How to manage a losing position in Oncolytics Biotech Inc.Quarterly Portfolio Report & Real-Time Volume Analysis - Newser
Does Oncolytics Biotech Inc. show high probability of reboundEarnings Growth Report & Entry Point Strategy Guides - Newser
Leading vs lagging indicators on Oncolytics Biotech Inc. performance2025 Trade Ideas & AI Based Buy/Sell Signal Reports - Newser
How to forecast Oncolytics Biotech Inc. trends using time seriesQuarterly Earnings Report & Consistent Profit Trading Strategies - Newser
Can Oncolytics Biotech Inc. navigate macro headwindsWeekly Loss Report & Daily Risk Controlled Trade Plans - خودرو بانک
Can swing trading help recover from Oncolytics Biotech Inc. lossesMarket Volume Report & Safe Entry Point Alerts - Newser
Is Oncolytics Biotech Inc. likely to announce a buybackAnalyst Downgrade & Safe Capital Growth Trade Ideas - خودرو بانک
Is Oncolytics Biotech Inc. still worth holding after the dip2025 Price Momentum & Reliable Volume Spike Trade Alerts - Newser
Oncolytics Biotech Inc. stock retracement – recovery analysisTrade Ideas & Verified Technical Signals - Newser
Applying big data sentiment scoring on Oncolytics Biotech Inc.Market Sentiment Summary & High Conviction Buy Zone Picks - Newser
Can Oncolytics Biotech Inc. reach all time highs this yearEarnings Summary Report & Verified Stock Trade Ideas - خودرو بانک
Quantitative breakdown of Oncolytics Biotech Inc. recent moveWeekly Profit Report & Fast Gaining Stock Reports - Newser
Can momentum traders help lift Oncolytics Biotech Inc.July 2025 Outlook & Fast Entry High Yield Tips - Newser
Can Oncolytics Biotech Inc. stock outperform in a bear marketPortfolio Growth Summary & High Win Rate Trade Tips - خودرو بانک
How to use a screener to detect Oncolytics Biotech Inc. breakoutsMarket Growth Summary & Fast Gain Swing Trade Alerts - Newser
Cellectar Biosciences shares fall 1.24% premarket as Oncolytics Biotech Inc. gains FDA approval for breakthrough therapies. - AInvest
How hedge fund analytics apply to Oncolytics Biotech Inc. stock2025 Valuation Update & Advanced Technical Analysis Signals - Newser
What’s the recovery path for long term holders of Oncolytics Biotech Inc.Earnings Performance Report & Stepwise Entry and Exit Trade Signals - Newser
Oncolytics Biotech shares rise 8.70% premarket after providing updated clinical safety data for pelareorep. - AInvest
What technical models suggest about Oncolytics Biotech Inc.’s comebackWeekly Stock Report & Safe Capital Growth Trade Ideas - Newser
What moving averages say about Oncolytics Biotech Inc.Inflation Watch & Target Return Focused Picks - Newser
Using data filters to optimize entry into Oncolytics Biotech Inc.July 2025 Short Interest & Verified High Yield Trade Plans - Newser
Tools to assess Oncolytics Biotech Inc.’s risk profileGap Down & Fast Entry and Exit Trade Plans - Newser
Does Oncolytics Biotech Inc. qualify in momentum factor screening2025 Market Sentiment & Safe Entry Trade Reports - Newser
Using portfolio simulators with Oncolytics Biotech Inc. included2025 Top Decliners & Long-Term Safe Investment Plans - Newser
FDA Fast-Track Cancer Treatments Drive Market Surge as Innovations Accelerate - Baystreet.ca
Oncolytics Biotech Inc. recovery potential after sell off2025 Top Decliners & Fast Gain Swing Trade Alerts - Newser
Trend analysis for Oncolytics Biotech Inc. this weekJuly 2025 Institutional & Technical Buy Zone Confirmation - Newser
Cellectar Biosciences shares fall 1.45% after-hours as Oncolytics Biotech Inc. gains regulatory momentum. - AInvest
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands - The Ritz Herald
Oncolytics Biotech Updates Pelareorep Safety Data for Gastrointestinal Tumors - TipRanks
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors - Barchart.com
Published on: 2025-09-02 05:28:33 - Newser
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):